Skip to main content

Mechanisms · Mechanism of Action

Ibogaine Pharmacokinetics

Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination — including the long noribogaine tail that drives the post-flood telemetry window.

DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team

Quick Answer

What is ibogaine pharmacokinetics in ibogaine pharmacology?

Ibogaine is rapidly absorbed orally, hepatically O-demethylated by CYP2D6 to noribogaine, and distributed broadly (high lipophilicity, large volume of distribution). Parent ibogaine has a plasma half-life of roughly 4-7 hours, but noribogaine has a much longer elimination tail — measurable for days to weeks. CYP2D6 polymorphisms (poor, intermediate, extensive, ultra-rapid metabolizers) substantially affect both peak ibogaine concentrations and the rate of noribogaine formation, which is why MindScape includes pharmacogenomic screening in eligibility workup.

Reviewed by Dr. Arellano, M.D. — May 2026

Absorption and distribution

Ibogaine is administered orally as the hydrochloride salt (HCl). Oral bioavailability is moderate; peak plasma concentrations occur within 1-3 hours of ingestion.

Both ibogaine and noribogaine are highly lipophilic and accumulate in adipose and other lipid-rich tissues. This accounts for the large apparent volume of distribution and contributes to the long terminal elimination phase observed in pharmacokinetic studies.

CYP2D6 metabolism to noribogaine

Ibogaine is O-demethylated by hepatic CYP2D6 to noribogaine, which is itself pharmacologically active.

CYP2D6 is highly polymorphic. Poor metabolizers (≈ 5-10% of European-ancestry populations) convert ibogaine to noribogaine more slowly, leading to higher and more prolonged ibogaine concentrations. Ultra-rapid metabolizers do the opposite. This is why MindScape includes pharmacogenomic screening in the eligibility workup where indicated.

  • Poor metabolizers: prolonged ibogaine exposure, slower noribogaine generation — adjust dose or defer.
  • Intermediate metabolizers: moderate impact, standard protocol with closer monitoring.
  • Extensive (normal) metabolizers: standard PK profile.
  • Ultra-rapid metabolizers: faster ibogaine clearance, potentially blunted clinical effect.

Elimination — the long noribogaine tail

Parent ibogaine's plasma half-life is ≈ 4-7 hours. Noribogaine's half-life is much longer — Glue et al. (2016) report estimates ranging from 28 to 49 hours after single oral dosing in opioid-dependent patients.

This long noribogaine tail is why MindScape maintains continuous cardiac telemetry for 72-96 hours post-flood dose: it covers the window during which noribogaine concentrations remain pharmacologically active.

Targets

  • CYP2D6
  • Noribogaine
  • Plasma protein binding
  • Adipose distribution

Citations & Reading

  • Glue P, et al. (2016). Clinical Pharmacology in Drug Development, 5(6), 460-468.
  • Mash DC, et al. (2018). Frontiers in Pharmacology, 9, 529.
  • Knuijver T, et al. (2022). Addiction, 117(1), 118-128.

For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.

Related mechanisms

Clinical Calls

Have a question about this mechanism?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation